Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD45 Antibodies and Alemtuzumab Conditioning for Allo-HSCT
NCT00056966Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Nov 2002
- Primary completion
- May 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of YTH25.4 + YTH54.12 in hematologic malignancy (2 arms), sponsored by Baylor College of Medicine. Primary endpoints: Non-relapse mortality at 100 days and Graft rejection at 100 days. Started Nov 2002; status: completed.
02
Drugs
YTH25.4 + YTH54.12
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00056966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056966.